Saturday 17 October 2026 Export BBLG’s income statement to Excel — free account

Bone Biologics Corp.

In the quarter to June 2026, EPS grew 67.7% and free cash flow fell 13.0%, each against the same quarter a year earlier.

0.40 0.01 +2.56%

Follow BBLG

Alert me

Market cap: $1.1M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 1.07

Revenue —

Net Income (2.89)

Free Cash Flow (2.63)

Net Debt (4.03)

Current Ratio 8.67

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 0.18

Past 5Y EPS Growth —

This Y EPS Growth 53.58%

Next Y EPS Growth 45.53%

Next Y revenue growth —

Next 5Y EPS Growth 81.18%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 1.89%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2020	Powerpack
2019	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	3	3	5	4
Receivables	—	—	0	0
Inventory	—	—	—	—
Other	0	0	0	0
	4	4	6	4

	2023	2024	2025	Q'26
Payables	0	0	0	1
ST’ Debt	—	—	—	—
Other	0	0	0	0
	1	0	0	1

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	(3.30%)

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(1)	—	—	—
’25	(1)	0	(1)	(1)	(3)
’24	(1)	(1)	(1)	(1)	(4)
’23	(1)	(4)	(3)	(2)	(10)
’22	(1)	0	0	(2)	(4)
’21	0	(1)	0	0	(1)
’20	—	0	0	0	0

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(1)	—	—	—
’25	(1)	0	(1)	(1)	(3)
’24	(1)	(1)	(1)	(1)	(4)
’23	(1)	(4)	(3)	(2)	(10)
’22	(1)	0	0	(2)	(4)
’21	0	(1)	0	0	(1)
’20	—	0	0	0	0

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.43)	(0.43)	—	—	—
’25	(1.92)	(1.33)	(0.37)	(0.14)	(2.65)
’24	(7.86)	(4.02)	(14.22)	(1.16)	(28.97)
’23	(331.61)	(31.31)	(29.27)	187.81	(204.02)
’22	(100.88)	(72.06)	(172.94)	143.97	(187.16)
’21	(213.72)	(243.52)	(245.00)	198.33	(511.06)
’20	—	(0.13)	(0.14)	(0.04)	(903.35)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	71,639.95	36,359.97	18,359.98	14,400.00	9,000.00	4,651.20	256.32	17.46	4.80	1.30	Analyst estimates 2026–2028 Powerpack
	High	185,399.86	212,399.83	107,999.91	93,599.99	27,000.00	27,000.36	9,763.20	576.00	38.04	7.74
People
People	Employees	—	—	—	—	2	2	2	2	2	2
	Revenue/emp, $m	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	0.00	0.00	0.00	0.00	—	—	—	—	—	—
	EBT	(26)	(7)	(4)	(3)	(2)	(2)	(1)	(9)	(4)	(3)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	(26)	0	(4)	(3)	(2)	(2)	(1)	(9)	(4)	(3)
	Depreciation	0	0	0	0	—	—	—	—	—	—
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	(17.25)	(4.50)	(528.93)	(676.95)	(903.35)	(511.06)	(187.16)	(204.02)	(28.97)	(2.65)
	Cash flow	(4.87)	(2.14)	(488.68)	(637.49)	(213.45)	(383.94)	(451.51)	(217.67)	(16.30)	(2.29)
	Capex	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Free cash flow	(4.87)	(2.14)	(488.68)	(637.49)	(213.45)	(383.94)	(451.51)	(217.67)	(16.30)	(2.29)
	Book value	(5.56)	(5.39)	(1,023.60)	(2,326.98)	(6,846.15)	2,054.84	752.82	66.21	13.77	4.58
	Shares, m	2	2	0	0	0	0	0	0	0	1
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(7)	(3)	(4)	(3)	0	(1)	(4)	(10)	(4)	(3)
	Capex	—	—	—	—	—	—	—	—	—	—
	Free cash flow	(7)	(3)	(4)	(3)	0	(1)	(4)	(10)	(4)	(3)
Balance, $m
Balance, $m	Working capital	(1)	0	(9)	(1)	(14)	7	6	3	3	5
	Total debt	9	8	9	11	12	—	—	—	—	—
	Net debt	8	8	8	11	12	(7)	(8)	(3)	(3)	(5)
	Shareholders’ equity	(8)	(8)	(9)	(12)	(14)	7	6	3	3	5
Returns, %
Returns, %	ROA	(3,457.87)	(2,011.58)	(508.72)	(639.25)	(11,848.70)	(48.04)	(19.57)	(146.30)	(192.78)	(64.39)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	(1,662.67)	(4,680.12)
	ROE	308.82	84.15	52.14	33.47	14.28	45.26	(23.71)	(202.15)	(229.26)	(70.17)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
PTIX Atrinsic Inc.	$1.3M	0.3×	—	+34.31% (above 0%: growing)	n/m	+46.07% (above 0%: growing)	0.00%	0.00%	Compare
SPRC SciSparc Ltd.	$1.2M	— (loss-making)	7.9×	—	n/m	+14.95% (above 0%: growing)	35.75%	0.00%	Compare
CYTOF Altamira Therapeutics Ltd.	$1.1M	— (loss-making)	— (loss-making)	—	n/m	+85.35% (above 0%: growing)	(157.79%)	0.00%	Compare
BBLG Bone Biologics Corp.	$1.1M	— (loss-making)	—	—	n/m	−12.97% (below 0%: shrinking)	—	0.00%
BPTH Bio-Path Holdings, Inc.	$1.1M	— (loss-making)	— (loss-making)	—	n/m	+98.68% (above 0%: growing)	0.00%	0.00%	Compare
CRIS Curis, Inc.	$1.1M	— (loss-making)	— (loss-making)	−65.98% (below 0%: shrinking)	n/m	−20.44% (below 0%: shrinking)	100.00%	0.00%	Compare
MNTRQ 9 Meters Biopharma, Inc.	$1.0M	— (loss-making)	—	−25.99% (below 0%: shrinking)	n/m	+0.01% (above 0%: growing)	0.00%	0.00%	Compare
ZVSA ZyVersa Therapeutics, Inc.	$970.0K	— (loss-making)	—	—	n/m	+54.91% (above 0%: growing)	0.00%	0.00%	Compare
LYRA Lyra Therapeutics, Inc.	$870.0K	— (loss-making)	— (loss-making)	−96.65% (below 0%: shrinking)	n/m	+45.44% (above 0%: growing)	100.00%	(101,685.71%)	Compare
Median of peers	$1.1M	—	—	−45.99%	—	+45.76%	0.00%	0.00%

All 614 Biotechnology stocks →